How Biomarkers and AKT Inhibition Are Becoming Part of the mHSPC Landscape

The treatment paradigm for metastatic hormone-sensitive prostate cancer is rapidly shifting toward biomarker-guided decision-making. Gordon A. Brown, DO, FACOS, emphasizes that the primary takeaway from CAPItello-281 (NCT04493853) is the necessity of routine PTEN testing, particularly through immunohistochemistry, to identify patients eligible for targeted treatment intensification strategies.

Brown explains that therapeutic discussions have evolved from choosing between doublet and triplet therapy toward integrating molecular data into frontline decisions. Alongside homologous recombination repair alterations and PSMA-based approaches, PTEN deficiency now represents another actionable biomarker that can guide therapy selection using evidence from prospective phase 3 trials.

Looking forward, Brown positions AKT inhibition as a biologically matched therapy for PTEN-deficient disease, ideally introduced early to prevent treatment escape through alternative signaling pathways. He underscores that optimal care will depend on systematic biomarker testing, thoughtful sequencing, and individualized patient discussions, marking a continued transition toward precision medicine in advanced prostate cancer.